Department of Gastrointestinal Tumor Pathology of Cancer Institute and General Surgery Institute, the First Hospital of China Medical University, Shenyang 110001, China.
Chin J Cancer Res. 2013 Dec;25(6):704-14. doi: 10.3978/j.issn.1000-9604.2013.11.11.
To explore the relationship between peroxisome proliferator activated receptor-gamma (PPARγ) and peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) expression in gastric carcinoma (GC), and analyze their correlations with clinicopathological features and clinical outcomes of patients.
The two-step immunohistochemical method was used to detect the expression of PPARγ and PGC-1 in 179 cases of GC, and 108 cases of matched normal gastric mucosa. Besides, 16 cases of fresh GC specimens and corresponding normal gastric mucosa were detected for PGC-1 expression with Western blotting.
The positive rates of PPARγ and PGC-1 expression were significantly lower in GC (54.75%, 49.16%) than in normal gastric mucosa (70.37%, 71.30%), respectively (P<0.05). The decreased expression of PGC-1 in GC was confirmed in our Western blot analysis (P=0.004). PPARγ and PGC-1 expressions were related to Lauren's types of GC (P<0.05). Positive correlation was found between PPARγ and PGC-1 expression in GC (rk=0.422, P<0.001). The survival time of PPARγ negative and positive patients was 36.6±3.0 vs. 38.5±2.7 months, and no statistical difference was found between the 5-year survival rates of two groups (34.4% vs. 44.1%, P=0.522, log-rank test); the survival time of PGC-1 negative and positive patients was 36.2±2.8 vs. 39.9±2.9 months, while no statistical difference was found between the 5-year survival rates of the two groups (32.0% vs. 48.2%, P=0.462, log-rank test).
Decreased expression of PPARγ and PGC-1 in GC was related to the Lauren's classification. Their expressions in GC were positively correlated, indicating that their functions in gastric carcinogenesis may be closely related.
探讨过氧化物酶体增殖物激活受体-γ（PPARγ）和过氧化物酶体增殖物激活受体-γ共激活因子-1（PGC-1）在胃癌（GC）中的表达关系，并分析其与患者临床病理特征及临床结局的关系。
采用两步免疫组化法检测 179 例 GC 及 108 例配对正常胃黏膜组织中 PPARγ和 PGC-1 的表达，并用 Western blot 法检测 16 例新鲜 GC 标本及其相应正常胃黏膜组织中 PGC-1 的表达。
GC 中 PPARγ和 PGC-1 的阳性表达率分别为 54.75%（101/186）和 49.16%（92/186），明显低于相应正常胃黏膜组织的 70.37%（79/112）和 71.30%（80/112）（P<0.05）。Western blot 分析也证实 GC 中 PGC-1 的表达下调（P=0.004）。PPARγ和 PGC-1 的表达与 GC 的 Lauren 分型有关（P<0.05）。GC 中 PPARγ和 PGC-1 的表达呈正相关（rk=0.422，P<0.001）。PPARγ阴性和阳性患者的生存时间分别为 36.6±3.0 个月和 38.5±2.7 个月，两组 5 年生存率差异无统计学意义（34.4%比 44.1%，P=0.522，log-rank 检验）；PGC-1 阴性和阳性患者的生存时间分别为 36.2±2.8 个月和 39.9±2.9 个月，两组 5 年生存率差异无统计学意义（32.0%比 48.2%，P=0.462，log-rank 检验）。
GC 中 PPARγ和 PGC-1 的表达下调与 Lauren 分型有关。GC 中它们的表达呈正相关，提示它们在胃癌发生中的作用可能密切相关。
